4 results match your criteria: "Complexo Universitario Hospitalario de Ourense.[Affiliation]"
Quality indicators for the diagnosis and treatment of breast cancer integrated assistance: A critical appraisal.
Semergen
January 2024
Department of Preventive Medicine and Public Health, University of Granada, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Spain; Instituto de Investigación Biosanitaria IBS, Granada, Spain.
Introduction: Quality indicators (QIs) are essential for adequate control of the health care management process, recognizing areas of improvement and providing solutions. We aimed to evaluate the Integrated Breast Cancer (BC) Care Process QIs.
Methods: We studied 487 consecutive BC cases diagnosed from November 1st, 2013, to November 30th, 2019, in a Spanish healthcare area, and we estimated the associated QIs.
Evaluation of the Use of Shared Decision Making in Breast Cancer: International Survey.
Int J Environ Res Public Health
February 2021
Department of Preventive Medicine and Public Health, University of Granada, 18014 Granada, Spain.
Objectives: To assess shared decision-making (SDM) knowledge, attitude and application among health professionals involved in breast cancer (BC) treatment.
Materials And Methods: A cross-sectional study based on an online questionnaire, sent by several professional societies to health professionals involved in BC management. There were 26 questions which combined demographic and professional data with some items measured on a Likert-type scale.
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
Future Oncol
May 2021
Department of Medical, Lilly, Madrid, 28108, Spain.
Article Synopsis
- A retrospective study was conducted across 20 hospitals in Spain to analyze the use and effectiveness of ramucirumab in treating advanced gastric cancer (AGC) and gastroesophageal junction adenocarcinoma (GEJ) in patients between December 2015 and December 2018.
- The study included 317 patients, with the majority receiving a combination treatment of ramucirumab and paclitaxel; most patients were around 62.5 years old and predominantly male.
- Results showed that the median progression-free survival was 3.9 months for combination therapy and 2.0 months for monotherapy, while overall survival was 7.4 months and 4.3 months, respectively, aligning with existing
[Mantle cell lymphoma with intestinal involvement].
Rev Esp Enferm Dig
March 2012
Servicio de Aparato Digestivo, Complexo Universitario Hospitalario de Ourense.